Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Growth in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 457,100 shares, an increase of 61.1% from the November 30th total of 283,800 shares. Based on an average trading volume of 350,200 shares, the days-to-cover ratio is currently 1.3 days. Currently, 17.1% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Institutional Trading of Aligos Therapeutics

An institutional investor recently raised its position in Aligos Therapeutics stock. Acadian Asset Management LLC lifted its holdings in Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 26.1% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 829,485 shares of the company’s stock after acquiring an additional 171,490 shares during the quarter. Acadian Asset Management LLC owned 1.06% of Aligos Therapeutics worth $289,000 at the end of the most recent quarter. 60.43% of the stock is owned by hedge funds and other institutional investors.

Aligos Therapeutics Stock Performance

Aligos Therapeutics stock opened at $41.15 on Friday. Aligos Therapeutics has a fifty-two week low of $6.76 and a fifty-two week high of $44.39. The stock has a market cap of $147.65 million, a P/E ratio of -3.09 and a beta of 2.71. The firm’s fifty day moving average price is $22.23 and its 200-day moving average price is $15.23.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. The firm had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $1.00 million. During the same quarter in the previous year, the business earned ($10.25) EPS. On average, analysts predict that Aligos Therapeutics will post -10.36 earnings per share for the current year.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).